SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is trending as investors aggressively target the stock due to a combination of extreme short interest, a very low tradable float, and high-frequency volatility that has triggered multiple trading halts. The community is heavily divided, with bulls pointing to a classic short squeeze setup and potential momentum, while bears highlight historical reverse splits, lack of consistent profitability, and concerns over a potential pump-and-dump scheme.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are currently in the spotlight as investors react to a significant earnings beat, with the community actively debating whether the platform's high-margin monetization and AI ad-tool potential will finally overcome ongoing price volatility and institutional short positioning.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors react to the NOAA determination that the company's deep-seabed mining application is in full compliance, fueling community anticipation for accelerated permitting and long-term supply dominance. Traders are actively discussing the potential for a short squeeze and waiting for further catalysts, such as the Allseas partnership extension, to sustain upward momentum.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is seeing strong momentum as the community focuses on its strategic transition toward AI infrastructure and high-capacity optical networking. Investors are actively discussing the company's recent partnership with Nvidia and the potential for a long-term turnaround, leading to increased institutional interest and bullish sentiment surrounding its pivot into AI data centers.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to a combination of clinical-stage momentum, a private placement financing announcement, and ongoing speculative chatter regarding a potential short squeeze. Investors are actively debating the company's long-term pivot toward autoimmune therapies and the impact of recent technical events, including a reverse stock split, on the stock's future liquidity and volatility.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS is trending due to significant volatility following a reverse stock split, with traders closely monitoring the ticker as a potential low-float play. The community remains deeply divided, with some betting on parabolic squeeze mechanics while others caution against the stock's fundamental weaknesses and the risk of further dilution.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox shares plunged following a significant cut to their annual bookings forecast, driven by engagement friction from new child-safety and age-verification protocols. Community discussion is sharply divided between investors viewing the selloff as an oversold opportunity in a dominant gaming platform and critics citing long-term concerns regarding platform monetization and regulatory scrutiny.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending amid a volatile reaction to blockbuster earnings and a significant stock buyback program, as investors weigh massive AI-driven storage demand against a parabolic stock rally. The community remains deeply divided between those betting on continued growth fueled by long-term contracts and those bracing for a potential correction following an extended period of unchecked momentum.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is attracting significant attention as investors speculate on potential license agreements and semiconductor super-cycle tailwinds, with community discussion intensely focused on technical patent applications, the impact of Synopsys collaboration, and the company's role in advancing GaN and GAA transistor efficiency. While bulls point to high-volume price breakouts as evidence of a shift in institutional sentiment, skeptics remain vocal about the lack of recurring revenue and the history of delayed commercialization milestones.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market scrutinizes its April delivery results, which triggered volatility amid ongoing debates about the companys growth trajectory, competitive landscape, and aggressive institutional short activity. Investors remain deeply divided, with many debating the impact of upcoming model launches and profitability against persistent concerns regarding market manipulation and sector-wide headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sunshine Biopharma (SBFM) rose 11% on Thursday morning after the company announced that its Canadian unit, Nora Pharma, launched a generic version of Bristol-Myers Squibb’s Pravachol.The drug, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/10/20251016_SBFM_Press-Release_Launches-Pravastatin.pdf">called</a> Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.Nora Pharma’s Pravastatin is available in strengths of 10 mg, 20 mg, and 40 mg, and comes in bottles of 100 tablets.Sunshine Biopharma said that the Canadian market of cholesterol-lowering drugs is estimated to reach $582 million by the end of 2025 and $1.07 billion by 2033.Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada, and more than 12 additional drugs are scheduled to be launched in 2026. The company is also seeking to develop drug candidates in the treatment of liver cancer and coronavirus infections.On Stocktwits, retail sentiment around SBFM stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_10_55_53_AM_png_97567a6c3b.webp" alt="SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company has a bright future.<stembedurl>https://stocktwits.com/Knowledgeworthmore/message/632572691</stembedurl>Another said that they intend to hold the stock long term.<stembedurl>https://stocktwits.com/BanditKnight47/message/632549060</stembedurl>In July, Sunshine Bioopharma <a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-soars-after-launch-of-first-biosimilar-in-10-b-canadian-market-retail-bulls-charge-in/chFjax5Rchk">introduced</a> its first biosimilar drug, Niopeg, to the Canadian market, to treat the risk of infection in cancer patients undergoing chemotherapy. In June, a generic version of Neurontin, Gabapentin, was launched for treating neuropathic pain and epilepsy.SBFM stock is down by 29% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-draws-investor-interest-as-european-regulator-reportedly-terms-door-safety-a-priority/ch6p3LDR3nA">Tesla Stock Draws Investor Interest As European Regulator Reportedly Terms Door Safety A Priority</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.

Equity

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.


Retail chatter around Sunshine Biopharma surged late Wednesday after the company introduced Niopeg, its first biosimilar drug, into the Canadian market,&nbsp;sending its stock soaring by nearly 14% — its best session in over seven months.The treatment, developed by its subsidiary Nora Pharma, is a pegfilgrastim biosimilar to Neulasta, which is commonly used to reduce the risk of infection in cancer patients undergoing chemotherapy.Niopeg is supplied in a 6mg/0.6mL prefilled syringe and is designed for patients with non-myeloid cancers.&nbsp;The company noted that global demand for Neulasta and similar drugs was worth approximately $4.5 billion last year, with expectations that it could rise to $9.2 billion by 2033, driven by increasing cancer cases and wider chemotherapy use.Canada, although a smaller part of the global market, still plays a disproportionately large role in biologics spending, according to a statement released by the company.&nbsp;The company said that Canada’s biologic drug sales totaled approximately $10 billion in 2020, accounting for roughly one-third of all pharmaceutical expenditures. Biosimilars, such as Niopeg, have gained more traction there in recent years, helped by provincial policies that encourage switching from branded biologics.The launch follows last month’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-unit-launches-generic-anticonvulsant-in-canada/chlayAARbC6">rollout of a generic version of Gabapentin</a>, a standard treatment for neuropathic pain and epilepsy, now available in 100 mg, 300 mg, and 400 mg doses, packaged in bottles of 500 capsules.Sunshine Biopharma states that it currently has 72 generic drugs on the Canadian market and plans to introduce more before the end of the year. It’s also pursuing drug candidates in areas such as liver cancer and treatments related to the coronavirus.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/SBFM">Sunshine Biopharma</a> was ‘extremely bullish’ amid a 6,200% jump in 24-hour message volume.One user noted that for the first time in a long while, Sunshine Biopharma was holding onto its gains following a news release, calling the chart setup strong and suggesting the stock could be gearing up for a multi-day run.<stembedurl>https://stocktwits.com/Tryitin/message/619793472</stembedurl>Another user pointed to the significance of the product launch into a $10 billion market and expressed confidence that the stock could see substantial upside in the coming days, even speculating about a potential move into double digits.<stembedurl>https://stocktwits.com/Tryitin/message/619760589</stembedurl>The stock has declined 42.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In

The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients.

Shares of Sunshine Biopharma Inc. (SBFM) were in the spotlight on Wednesday after the pharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/06/20250611_SBFM_Press-Release_Launches-Gabapentine-1.pdf">announced</a> that its Canadian unit, Nora Pharma, has launched a new generic prescription drug, Gabapentin.Gabapentin is an anticonvulsant medication used to treat neuropathic pain and epilepsy, as well as for the treatment of pain caused by various medical conditions by reducing excess excitation of the neural networks in the brain and spinal cord.Nora Pharma’s Gabapentin is available in strengths of 100 mg, 300 mg, and 400 mg and comes in bottles of 500 capsules.According to Sunshine Pharma, Canada represents approximately 1.2% of the global pharmaceutical market for Gabapentin, which was valued at $1.92 billion in 2024. It is projected to reach $3.07 billion, the company said.CEO Steve Slilaty said that the company is attempting to fortify its presence in Canada’s generic drugs market, valued at $9.4 billion. The market is forecasted to nearly double to $19.2 billion by 2032, he added.Sunshine Biopharma currently has 71 generic prescription drugs on the market in Canada, with over 12 additional drugs planned for launch in the remainder of 2025.On Stocktwits, retail sentiment around SBFM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_1_14_32_PM_png_31faf5b9e5.webp" alt="SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits" width="631" height="67"><figcaption>SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that short sellers will not risk shorting Sunshine owing to its significant institutional ownership, low float, and ‘HUGE potential.’<stembedurl>https://stocktwits.com/LH1975New/message/617532142</stembedurl><a href="https://stocktwits.com/symbol/SBFM">SBFM stock</a> is down by about 46% this year and has wiped out nearly three-quarters of its valuation over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/intelligent-bio-rises-on-partnership-with-smartox/chlaUpbRbCy">Intelligent Bio Rises On Partnership With Smartox To Expand US Market Presence: Retail Hopes The Stock To Hit $2.6</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion.

Sunshine Biopharma, Inc.'s stock rose over 3% on Monday, lifting retail investor sentiment, after the company said its Canadian subsidiary had launched a generic version of an oncology drug.Nora Pharma launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market, Sunshine said.&nbsp;The drug is indicated for advanced renal cell carcinoma, breast cancer in certain post-menopausal women, some neuroendocrine tumors and tuberous sclerosis-related brain tumors.&nbsp;Sunshine said Everolimus is available in 2.5 mg, 5 mg and 10 mg strengths in 30-tablet blister packs.The global Everolimus market is valued at $2.5 billion in 2023 and is projected to hit around $4.8 billion by 2032, the company said.&nbsp;The announcement sent message volume on Stocktwits about Sunshine Biopharma soaring over 14,700% in the 24 hours to late Monday, even as the stock slid over 1% in after-hours trading.Sentiment among retail traders flipped to ‘extremely bullish’ from ‘bearish’ a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SBFM_sentiment_and_message_volume_as_of_April_21_png_ee65768271.webp" alt="SBFM sentiment and message volume as of April 21.png" width="1318" height="316"><figcaption>SBFM sentiment and message volume as of April 21. | source: Stocktwits</figcaption></figure>One watcher took heart from Everolimus' sales projections and said it "is going to blow someday."<stembedurl>https://stocktwits.com/JdNews/message/612158515</stembedurl>Another user speculated that the company was soon going to form strategic partnerships.<stembedurl>https://stocktwits.com/contra7/message/612209836</stembedurl>Earlier this month, Sunshine reported new preclinical data for its K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma (HCC).&nbsp;Sunshine’s stock, which has a short interest of 6.6% according to Koyfin, has lost over half its value this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug

Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

Current Price	$0.9699
Prev Close	$0.9623
Open	$0.9699
Dividend Yield	0.00%
50-Day Moving Average	$1.07
Beta	1.89
Avg. Volume	36,047.65
PE Ratio	-0.65

52-Week High	$2.43
52-Week Low	$0.95
Market Capitalization	$4.72M
EPS (Annual)	-$1.44
Price to Book	0.20
Revenue Per Employee	$726,117.82

SBFM
Sunshine Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SBFM News

SBFMSunshine Biopharma Inc